Aesthetic treatments can help you maintain your youthful glow – The Business Times

AESTHETICS medicine encompasses non-invasive treatments that do not involve surgery and aim to improve or correct the appearance of patients. Less intensive than cosmetic surgery, aesthetics medicine procedures are carried out by doctors to give natural and reversible results. Depending on your areas of concern, different techniques may be employed in combination to produce the best results - there is no "cookie-cutter" approach to your skincare needs.

Our skin has three layers:

The epidermis, the outermost layer of skin, provides a waterproof barrier to protect our body from germs and harmful UV rays. Its bottom-most layer makes new skin cells, and these skin cells travel up to the top layer and flake off, about a month after they form. It also gives you your skin colour, due to the presence of special cells called melanocytes, which produce the pigment melanin.

The dermis, the middle layer, contains tough connective tissue, blood vessels, hair follicles, and sweat glands.

The hypodermis, the innermost layer, is made of fat and connective tissue.

Ageing happens in every layer of the skin. Changes within the skin's layers show themselves on the surface as signs of ageing.

In the epidermis, a slower cell turnover and reduction in lipid production on the skin's surface means rough and dry skin as we age. Our skin is less efficient at repairing itself from harmful infections and UV rays. This causes pigmentation problems, like sunspots.

In the dermis, from the age of 25, there is a 1 per cent annual decrease in collagen, one of the "building blocks" of the skin. Elastin also decreases as we age. Hence, the structure of the skin is compromised, and wrinkles and saggy skin start to appear.

In the deeper layers, the hypodermis, the changes to the size and number of fat cells leads to deep wrinkles and hollow cheeks.

Skin ageing manifests by:

Fine lines and wrinkles: The first noticeable sign of ageing from 25 onwards are fine lines and wrinkles, especially around your eyes. Your dermis, the second layer of your skin, contains the collagen and elastic fibres that keep young skin plump, taut and wrinkle-free. The amount of collagen and elastic fibres in your dermis dwindles as the years roll on. As a result, your skin becomes less elastic, sags and you start to see the tell-tale signs of wrinkles.

Open pores and sagging skin: Ageing causes your skin to lose its elasticity, which stretches your pores and make them look larger. The accumulation of excess oil, dead skin cells and dirt trapped inside your pores also enhances their appearance. Hormonal changes such as pregnancy, menstruation and puberty can also enlarge your pores.

Dry and dull skin: Your epidermis forms the outer layer of your skin - a physical barrier from the external environment. On average, your body will produce an entirely new epidermis about every 60 days. Cells on the surface of your skin rub and flake off, continuously being replaced with new ones from below.

As you get older, it takes longer for your epidermis to renew itself, hence, more dead skin cells accumulate on the top layer of our skin. This diffuses light away and produces a dull skin tone. In addition, as we age, oil production slows down and this makes our skin dry - we soon lose that "Korean glass-skin effect".

Hyperpigmentation

Melanocytes located in the epidermis produce pigment called melanin. Hyperpigmentation is caused by an overproduction of melanin in patches of the skin.

This overproduction is triggered by a variety of factors, including sun exposure, genetic factors, age, hormonal influences, and skin injuries or inflammation.

Common types of hyperpigmentation encountered in our population are:

Melasma: Melasma is a common skin problem among Asians. Women are far more likely than men to get melasma, especially during pregnancy. They present as brown to gray-brown patches, usually on the face. Most people get it on their cheeks, nose bridge, forehead, chin, and above their upper lip. It also can appear on other parts of the body that are exposed to sunlight, such as the forearms and neck.

Solar lentigo: Solar lentigo, also known as age spots, are non-cancerous lesions that occur on the sun-exposed areas of the body. These flat lesions usually have well-defined borders, are dark in colour, and have an irregular shape. The backs of hands and face are common areas.

The lesions tend to increase in number with age, making them common among the middle age and older population. Age spots occur in 50 per cent of women and 20 per cent of men over the age of 50, due to stimulation from UV rays.

Post-inflammatory hyperpigmentation (PIH): It is temporary pigmentation that follows injury, for example, a cut to the skin, or inflammation of the skin, for example, acne or eczema. PIH can occur in anyone, but is more common in darker-skinned individuals, in whom the colour tends to be more intense and persist for a longer period than in lighter skin.

Freckles: Freckles are common, especially among fairer-skinned individuals. They start early on in life, even in childhood, and are due to your genetic makeup and sun exposure.

Dull skin, enlarged pores, pigmentation - How can they be corrected?

Avoid sun exposure: Sun exposure is the main cause of ageing. Choose a sunscreen with "broad spectrum" protection, meaning that it protects against both UVA and UVB rays. UVA rays also contribute to skin cancer and premature aging, UVB rays are the main cause of sunburn and skin cancers.

Ensure your sunscreen has a SPF30 or higher. Physical sunscreen, those that contain zinc oxide or titanium dioxide, provide better sun protection compared to chemical sunscreens, and are less likely to clog pores and cause pimples.

Protect your eyes with sunglasses and cover up with a wide-brimmed hat or an umbrella. Limit your direct exposure to the sun, especially between 10am and 4pm, when UV rays are strongest. Avoid tanning beds, which can cause serious long-term skin damage and contribute to skin cancer.

Lightening creams: Abnormal accumulation of melanin results in hyperpigmentation. Lightening creams contain ingredients to reduce the production of melanin. Powerful lightening creams are available through a prescription from a doctor, while milder ingredients do not require a prescription.

Hydroquinone is a major ingredient in lightening creams. However, frequent adverse reactions experienced by patients, such as skin irritation and inflammation, have prompted research into other agents. Several alternatives such as tranexamic acid, and 4-n-butyl resorcinol, arbutin and kojic acid have been developed.

Lasers: There are many different lasers in the market, for many different types of indications. The property of the laser, which determines what it is used for, is the specific wavelength it emits. Different structures in the skin will absorb light energy at different wavelengths. Therefore, in pigmentation treatments, we can deliver light energy at the correct wavelength to heat up the pigmentation, while sparing the other nearby structures that absorb different wavelengths.

The pigmentation absorbs the light energy and is broken up into small fragments and eventually is cleared from the skin.

My personal favourite protocol is to use two very effective lasers for pigmentation treatment, via a Rejuvenation Laser protocol.

The Nd:YAG laser emits wavelengths of 1064nm and 532nm. It is a gentle cleansing machine that helps to remove surface dirt and oil, cleanse your skin, dry up pimples, build collagen and is very effective to break up pigmentation into small fragments.

The yellow laser, made in Germany, emits a wavelength of 577nm. It helps with improving radiance, giving you radiant skin, reducing redness and effectively vaporising pigmentation.

The Rejuvenation Laser is non-ablative, gentle and has no downtime.

Combined with a potent post-procedure serum, it synergistically enhances the anti-ageing effect of the laser protocol. The serum employs proteins secreted by umbilical cord-lining stem cells to produce collagen, restore healthy skin function and treat symptoms of ageing.

This series is produced in collaboration with The Aesthetics Medical Clinic

Continue reading here:
Aesthetic treatments can help you maintain your youthful glow - The Business Times

‘I just wish I could watch her grow up’: Stem cell match needed to save toddler’s life – CTV News London

LONDON, ONT. -- Nineteen-month old Savannah Hill was diagnosed with a rare form of childhood leukemia three months ago.

It broke my heart because she stopped walking and she stopped eating and she stopped playing, says Jessica Hill, Savannahs mom. It was even hard for her sister because she didnt know what was going on.

The family has been at Childrens Hospital in London for the past several months.

Savannah is currently undergoing a number of treatments, including chemotherapy, but what she ultimately needs to save her life is a stem-cell transplant.

Without transplant, we are looking at an even worse prognosis, so right now we are looking at this as the best results, and best prognosis getting a stem cell transplant, says Savannahs dad Lawrence Hill.

However, whats needed for a successful transplant is a stem cell match with Savannah and thats not something that is easy to come by.

We need to make sure to find a suitable match for her and its very hard because its basically like youre looking for your genetic twin, Jessica explains.

Since its crucial for Savannah to find a match, the family is holding a stem cell drive this Saturday at White Oaks Mall.

There is also a GoFundMe set up for the family to help cover costs of transportation, nutrition, hospital residence, parking, rent, and more.

There will also be a drive the same day in Windsor at Canadian Blood Services.

I just wish I could watch her grow up and see the beautiful woman that she would become and how she can help others with her story and show shes a fighter, says Jessica.

The family hopes their story will encourage people to take 10 minutes out of their day to come to the drive.

Lawrence says those 10 minutes could potentially save Savannahs life.

We are going to move forward day by day one step at a time and we will pray for that match.

Stem cell drive dates and locations:

Anyone who cannot attend the drives and wants to donate can contact Canadian Blood Services in their area to ask how they can be tested to help Savannah Hill.

Read the original:
'I just wish I could watch her grow up': Stem cell match needed to save toddler's life - CTV News London

Stem Cell Treatments Market to Exhibit Impressive Growth of CAGR during the per – News by aeresearch

Latest Research Report on Stem Cell Treatments Market size | Industry Segment by Applications (Nerve Diseases, Immunological Diseases, Musculoskeletal Disorders, Cardiovascular Diseases, Gastrointestinal Diseases and Other), by Type (Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Cord Blood/Embryonic Stem Cells and Other Cell Sources), Regional Outlook, Market Demand, Latest Trends, Stem Cell Treatments Industry Growth, Share & Revenue by Manufacturers, Company Profiles, Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

New research report to its expanding repository. The research report, titled Stem Cell Treatments Market, mainly includes a detailed segmentation of this sector, which is expected to generate massive returns by the end of the forecast period, thus showing an appreciable rate of growth over the coming years on an annual basis. The research study also looks specifically at the need for Stem Cell Treatments Market.

Our Report Offerings Include:

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/72554

Report Scope:

The study includes the profiles of key players in the Stem Cell Treatments market with a significant global and/or regional presence. The Stem Cell Treatments market competition by Top Manufacturers Covers:

By Product:

By Application:

Points Covered in The Report:

Recent Industry Trend:

The report contains the profiles of various prominent players in the Global Stem Cell Treatments Market. Different strategies implemented by these vendors have been analyzed and studied to gain a competitive edge, create unique product portfolios and increase their market share. The study also sheds light on major global industry vendors. Such essential vendors consist of both new and well-known players. Besides, the business report contains important data relating to the launch of new products on the market, specific licenses, domestic scenarios and the strategies of the organization implemented on the market.

MAJOR TOC OF THE REPORT:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/72554

Read the rest here:
Stem Cell Treatments Market to Exhibit Impressive Growth of CAGR during the per - News by aeresearch

Reviewing National Research (NASDAQ:NRC) and US Stem Cell (NASDAQ:USRM) – Slater Sentinel

National Research (NASDAQ:NRC) and US Stem Cell (OTCMKTS:USRM) are both small-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for National Research and US Stem Cell, as reported by MarketBeat.

Valuation & Earnings

This table compares National Research and US Stem Cells revenue, earnings per share (EPS) and valuation.

National Research has higher revenue and earnings than US Stem Cell.

Institutional & Insider Ownership

39.6% of National Research shares are owned by institutional investors. 4.5% of National Research shares are owned by company insiders. Comparatively, 16.7% of US Stem Cell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares National Research and US Stem Cells net margins, return on equity and return on assets.

Risk & Volatility

National Research has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, US Stem Cell has a beta of 5.08, indicating that its stock price is 408% more volatile than the S&P 500.

Summary

National Research beats US Stem Cell on 7 of the 9 factors compared between the two stocks.

National Research Company Profile

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Companys portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Companys clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.

US Stem Cell Company Profile

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.

Continue reading here:
Reviewing National Research (NASDAQ:NRC) and US Stem Cell (NASDAQ:USRM) - Slater Sentinel

Report: Former Intercontinental Champion Working To Return To WWE Ring – Cultaholic

Throughout his early career, Daniel Bryan suffered at least 10 concussions, which caused a lesion in the brain and forced him into retirement into 2014. While Bryan was ultimately cleared by WWEs medical team in 2018 and has been wrestling in the company ever since, The American Dragon found it difficult to get cleared by WWE despite independent doctors declaring it safe for him to perform. This led to Bryan requesting his release from the company so he could wrestle in Ring Of Honor or New Japan Pro Wrestling, but WWE consistently denied his requests.

Now, a similar situation is seemingly affecting former Intercontinental Champion Santino Marella. The Milan Miracle was forced to retire in WWE in 2014 after undergoing neck surgery for the third time. However, after his release from the company in 2016, Marella came out of retirement and has been sporadically wrestling ever since. He most recently wrestled in the Womens Royal Rumble match as his twin sister Santina but wasnt cleared to take any bumps and eliminated himself from the match, despite wrestling a 10-minute match back in September against Simon Grimm at Josh Barnetts Bloodsport 2.

Marella is determined to end his career on his terms in WWE, however, and Dave Meltzer has reported in the Wrestling Observer Newsletter that the former Miss WrestleMania is travelling to Colombia to undergo stem cell treatment to repair his neck. Meltzer explained other wrestlers like RVD, Kevin Nash, Edge, and Sheamus have all undergone the same treatment and have credited it with helping them prolong their careers.

For the avoidance of doubt, Meltzer wrote: A huge thing that may even revolutionize careers is the stem cell treatment that a lot of wrestlers have used flying to Colombia. The idea is that it regrows tissue and discs and regenerates injuries. A lot of talent, Kevin Nash, Rey Mysterio, Rob Van Dam, Brian Cage, Edge, Sheamus and many others have gone there for treatment. Anthony Carelli (Santino Marella) is there this week and he noted on Sunday Nights Main Event in Canada that every wrestler who has gotten that treatment except Kurt Angle, whose damage must have been so bad that it simply was beyond repair, has ended up with good results from it. While Edge never talked about it, that is said by others to be part of what has allowed him to return. Carelli, who has had back and neck issues that ended his career, is looking to return to wrestle and end his career on his own terms, as well as go back to competing in age group judo.

See the original post here:
Report: Former Intercontinental Champion Working To Return To WWE Ring - Cultaholic

Life and death in Wuhan: On the front lines fighting coronavirus – Nikkei Asian Review

WUHAN, China (Caixin) -- In the coronavirus epidemic, doctors on the front lines take on the greatest risk and best understand the situation. Peng Zhiyong, director of acute medicine at the Wuhan University South Central Hospital, is one of those doctors.

In an interview on Tuesday with Caixin, Peng described his personal experiences in first encountering the disease in early January and quickly grasping its virulent potential and the need for stringent quarantine measures.

As the contagion spread and flooded his ICU, the doctor observed that three weeks seemed to determine the difference between life and death. Patients with stronger immune systems would start to recover in a couple of weeks, but in the second week some cases would take a turn for the worse.

In the third week, keeping some of these acute patients alive might require extraordinary intervention. For this group, the death rate seems to be 4% to 5%, Peng said. After working 12-hour daytime shifts, the doctor spends his evenings researching the disease and has summarized his observations in a thesis.

The doctors and nurses at his hospital are overwhelmed with patients. Once they don protective hazmat suits, they go without food, drink and bathroom breaks for their entire shifts. That's because there's aren't enough of the suits for a mid-shift change, he said.

Over the past month on the front lines of the coronavirus battle, Peng has been brought to tears many times when forced to turn away patients for lack of staffing and beds. He said what really got to him, though, was the death of an acutely ill pregnant woman when treatment stopped for lack of money -- the day before the government decided to pick up the costs of all coronavirus treatments.

Here is our interview with the ICU doctor:

Screening criteria were too tough in the beginning

Caixin: When did you encounter your first novel coronavirus patient?

Peng Zhiyong: Jan. 6, 2020. There was a patient from Huanggang who had been refused by multiple hospitals and was sent to the South Central Hospital emergency room. I attended the consultation. At the time, the patient's illness was already severe, and he had difficulty breathing. I knew right then that he had contracted this disease. We debated at length whether to accept the patient. If we didn't, he had nowhere to go; if we did, there was a high likelihood the disease would infect others. We had to do a very stringent quarantine. We decided to take the patient in the end.

I called the hospital director and told him the story, including the fact that we had to clear the hospital room of other patients and to remodel it after SARS standards by setting up a contamination area, buffer area and cleaning area while separating the living areas of the hospital staff from the patients'.

On Jan. 6, with the patient in the emergency room, we did quarantine remodeling in the emergency room and did major renovations to the intensive care unit. South Central Hospital's ICU has 66 beds in total. We kept a space dedicated to coronavirus patients. I knew the infectiousness of the disease. There were bound to be more people coming in, so we set aside 16 beds. We did quarantine renovations on the infectious diseases area because respiratory illnesses are transmitted through the air, so even air has to be quarantined so that inside the rooms the air can't escape. At the time, some said that the ICU had a limited number of beds and 16 was excessive. I said it wasn't excessive at all.

Caixin: You predicted in January that there would be person-to-person transmission and even took quarantine measures. Did you report the situation to higher-ups?

Peng: This disease really did spread very fast. By Jan. 10, the 16 beds in our ICU were full. We saw how dire the situation was and told the hospital's leadership that they had to report even higher. Our head felt it was urgent too, and reported this to the Wuhan city health committee. On Jan. 12, the department sent a team of three specialists to South Central to investigate. The specialists said that clinical symptoms really resembled SARS, but they were still talking about diagnosis criteria, that kind of stuff. We replied that those standards were too stringent. Very few people would get diagnosed based on those criteria. The head of our hospital told them this multiple times during this period. I know other hospitals were doing the same.

Before this, the specialists had already gone to Jinyintan Hospital to investigate and made a set of diagnosis criteria. You had to have had exposure to the South China Seafood Market, you needed to have had a fever and test positive for the virus. You had to meet all three criteria in order to be diagnosed. The third one was especially stringent. In reality, very few people were able to test for a virus.

On Jan. 18, the high-level specialists from the National Health Commission came to Wuhan, to South Central Hospital to inspect. I told them again that the criteria were too high. This way it was easy to miss infections. I told them this was infectious; if you made the criteria too high and let patients go, you're putting society in danger. After the second national team of specialists came, the criteria were changed. The number of diagnosed patients rose quickly.

Caixin: What made you believe the new coronavirus could be transmitted between people?

Peng: Based on my clinical experience and knowledge, I believed that the disease would be an acutely infectious one and that we needed high-level protection. The virus isn't going to change based on man's will. I felt we needed to respect it and act according to science. Heeding my requirements, South Central Hospital's ICU took strict quarantine measures, and as a result, our department only had two infections. As of Jan. 28, of the entire hospital's medical personnel, only 40 have been infected. This is way less compared with other hospitals in terms of percentage of total medical staff.

It pains us to see the coronavirus develop to such a desperate state. But the priority now is to treat people; do everything we can to save people.

Fatality rate for acute patients is 4% to 5%. Three weeks determine life and death

Caixin: Based on your clinical experience, what's the disease progression of the new coronavirus?

Peng: Lately I've been spending daytimes seeing patients in the ICU, then doing some research in the evenings. I just wrote a thesis. I drew on data from 138 cases that South Central Hospital had from Jan. 7 to Jan. 28 and attempted to summarize some patterns of the novel coronavirus.

A lot of viruses will die off on their own after a certain amount of time. We call these self-limited diseases. I've observed that the breakout period of the novel coronavirus tends to be three weeks, from the onset of symptoms to developing difficulties breathing. Basically going from mild to severe symptoms takes about a week. There are all sorts of mild symptoms: feebleness, shortness of breath, some people have fevers, some don't. Based on studies of our 138 cases, the most common symptoms in the first stage are fever (98.6% of cases), feebleness (69.6%), cough (59.4%), muscle pains (34.8%) and difficulties breathing (31.2%), while less common symptoms include headaches, dizziness, stomach pain, diarrhea, nausea and vomiting.

But some patients who enter the second week will suddenly get worse. At this stage, people should go to the hospital. Elderly with underlying conditions may develop complications; some may need machine-assisted respiration. When the body's other organs start to fail, that's when it becomes severe, while those with strong immune systems see their symptoms decrease in severity at this stage and gradually recover. So the second week is what determines whether the illness becomes critical.

The third week determines whether critical illness leads to death. Some in critical condition who receive treatment can increase their lymphocytes, a type of white blood cell, and see an improvement in their immune systems, and have been brought back, so to speak. But those whose lymphocyte numbers continue to decline, those whose immune systems are destroyed in the end, experience multiple organ failure and die.

For most, the illness is over in two weeks, whereas for those for whom the illness becomes severe, if they can survive three weeks they're good. Those that can't will die in three weeks.

Caixin: Could you give more details on clinical research? What percentage of cases develop from mild conditions to severe conditions? What percentage of serious cases develop into life-threatening ones? What is the mortality rate?

Peng: Based on my clinical observations, this disease is highly contagious, but the mortality rate is low. Those that progressed into the life-threatening stage often occurred in the elderly already with chronic diseases.

As of Jan. 28, of 138 cases, 36 were in the ICU, 28 recovered, five died. That is to say, the mortality rate of patients with severe conditions was 3.6%. Yesterday, Feb. 3, another patient died, bringing the mortality rate to 4.3%. Given patients in the ICU, it is likely to have more deaths. The mortality rate is also likely to edge up but not significantly.

Those hospitalized tend to have severe or life-threatening conditions. Patients with slight symptoms are placed in quarantine at home. We have not gathered data on the percentage of cases that progress from slight symptoms to serious symptoms. If a patient goes from serious conditions to life-threatening conditions, the patient will be sent to the ICU. Among 138 patients, 36 were transferred to the ICU, representing 26% of all patients. The percentage of deaths among life-threatening cases is about 15%. The mean period to go from slight conditions to life-threatening conditions is about 10 days. Twenty-eight patients recovered and were discharged. Right now, the recovery rate is 20.3% while other patients remain hospitalized.

It is notable that 12 cases were linked to South China Seafood Market; 57 were infected while being hospitalized, including 17 patients already hospitalized in other departments; and 40 medical staff, among 138 cases, as of Jan. 28. That demonstrates that a hospital is a high-risk zone and appropriate protection must be taken.

Caixin: What is the highest risk a seriously ill patient faces?

Peng: The biggest assault the virus launches is on a patient's immune system. It causes a fall in the count of lymphocytes, damage in the lungs and shortness of breath. Many serious patients died of choking. Others died of the failure of multiple organs following complications in their organs resulting from a collapse of the immune system.

Caixin: A 39-year-old patient in Hong Kong suffered from cardiac arrest, and he died quickly. A few patients did not have severe symptoms upon the onslaught of the virus, or in the early stages, but they died suddenly. Some experts argue that the virus triggers a cytokine storm, which ravages the stronger immune systems of young adults. Eventually excessive inflammations caused by cytokine result in the higher mortality rate. Have you seen such a phenomenon in the coronavirus outbreak?

Peng: Based on my observations, a third of patients exhibited inflammation in their whole body. It was not necessarily limited to young adults. The mechanism of a cytokine storm is about whole-body inflammation, which leads to a failure of multiple organs and quickly evolves into the terminal stage. In some fast-progressing cases, it took two to three days to progress from whole-body inflammation to the life-threatening stage.

Caixin: How do you treat serious and life-threatening cases?

Peng: For serious and life-threatening cases, our main approach is to provide oxygen, high-volume oxygen. At first noninvasive machine-pumped oxygen, followed by intubated oxygen if conditions worsen. For life-threatening cases, we use ECMO (extracorporeal membrane oxygenation, or pumping the patient's blood through an artificial lung machine). In four cases, we applied ECMO to rescue patients from the verge of death.

Currently there are no special drugs for the coronavirus. The primary purpose of the ICU is to help patients sustain the functions of their body. Different patients have different symptoms. In case of shortness of breath, we provided oxygen; in case of a kidney failure, we gave dialysis; in case of a coma, we deployed ECMO. We provide support wherever a patient needs it to sustain their life. Once the count of lymphocytes goes up and the immune system improves, the virus will be cleared. However, if the count of lymphocytes continues to fall, it is dangerous because the virus continues to replicate. Once a patient's immune system is demolished, it is hard to save a patient.

Caixin: There is news of some drugs that work. People are hopeful of U.S.-made remdesivir, which cured the first case in the United States. What do you think of the drugs?

Peng: There are no 2019 novel coronavirus-targeted drugs so far. Some patients may recover after taking some drugs along with supportive treatment. But such individual cases do not indicate the universal effect of the drugs. The effect is also related to how serious each case is and their individual health conditions. People want a cure urgently, and that is understandable. But we need to be cautious.

Caixin: Do you have any advice for coronavirus patients?

Peng: The most effective approach to the virus epidemic is to control the source of the virus, stem the spread of the virus and prevent human-to-human transmission. My advice for a patient is going to a special ward for infectious diseases, early detection, early diagnosis, early quarantine and early treatment. Once it has developed into a severe case, hospitalization is a must. It is better to contain the disease at an early stage. Once it reaches the life-threatening stage, it is way more difficult to treat it and requires more medical resources. With regard to life-threatening cases, try to save them with ICU measures to reduce the mortality rate.

Sad story of a pregnant patient

Caixin: How many patients with life-threatening conditions have you treated? How many have recovered?

Peng: As of Feb. 4, six patients in the ICU of South Central Hospital died. Eighty percent of them have been improving, a quarter are approaching their discharge and the remainder are still recovering in segregated wards.

The patient who impressed me most came from Huanggang. He was the first to be saved with the assistance of ECMO. He had contact with South China Seafood Market and was in very serious condition. He was transferred to the ICU and we saved him with ECMO. He was discharged from the hospital Jan. 28.

Caixin: What is your workload and pace like?

Peng: The ICU is overloaded. There are three patient wards with 66 beds in South Central Hospital, housing 150 patients. Since Jan. 7 when we received the first patient, no one took any leave. We took turns working in the ICU. Even pregnant medical staff did not take leave. After the epidemic got worse, none of the medical staff ever went home. We rest in a hotel near the hospital or in the hospital.

In the segregated ward, we wear level-3 protective gear. One shift is 12 hours for a doctor and eight hours for a nurse. Since protective gear is in a shortage, there is only one set for a medical staff member a day. We refrain from eating or drinking during our shift because the gear is no longer protective once we go to the washroom. The gear is thick, airtight and tough on our body. It felt uncomfortable at the beginning, but we are used to it now.

Caixin: Did you experience any danger? For example, in case of intubation, what do you do to prevent yourselves from being infected?

Peng: It is a new coronavirus. We are not sure of its nature and its path of spread. It is not true to say we are not afraid. Medical staff members do fear to some extent. But patients need us. When a patient is out of breath and noninvasive oxygen provision fails, we must apply intubation. The procedure is dangerous as the patient may vomit or spit. Medical staff are likely to be exposed to the danger of infection. We strictly require doctors and nurses to apply the highest-level protection. The biggest problem we face now is the shortage of protective gear. The protective stock for ICU staff is running low, although the hospital prioritizes the supply to us.

Caixin: Is there anything that moved you in particular? Did you cry?

Peng: I often cried because so many patients could not be admitted to the hospital. They wailed in front of the hospital. Some patients even knelt down to beg me to accept him into the hospital. But there was nothing I could do since all beds were occupied. I shed tears while I turned them down. I've run out of tears now. I have no other thoughts but to try my best to save more lives.

The most saddest thing was a pregnant woman from Huanggang. She was in very serious condition. Nearly 200,000 yuan ($28,700) was spent after more than a week in the ICU. She was from the countryside, and the money for hospitalization was borrowed from her relatives and friends. Her condition was improving after the use of ECMO, and she was likely to survive. But her husband decided to give up. He cried for his decision. I wept too because I felt there was hope for her to be saved. The woman died after we gave up. And exactly the next day, the government announced a new policy that offers free treatment for all coronavirus-infected patients. I feel so sorry for that pregnant woman.

The deputy director of our department told me one thing, and he cried too. Wuhan 7th Hospital is in a partnership with our hospital, South Central Hospital. The deputy director went there to help in their ICU. He found that two-thirds of the medical staff in the ICU were already infected. Doctors there were running "naked" as they knew they were set to be infected given the shortage of protective gear. They still worked there nonetheless. That was why ICU medical staff were almost all sickened. It is too tough for our doctors and nurses.

Read the original story here.

Caixinglobal.com is English-language online news portal of Chinese financial and business news media group Caixin. Nikkei recently agreed with the company to exchange articles in English.

See the article here:
Life and death in Wuhan: On the front lines fighting coronavirus - Nikkei Asian Review

Stem Cell Alopecia Treatment Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 – Instant Tech…

New Jersey, United States The report is a comprehensive research study of the global Stem Cell Alopecia Treatment market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Stem Cell Alopecia Treatment global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

This report covers a comprehensive study of the data affecting the Stem Cell Alopecia Treatment market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Stem Cell Alopecia Treatment market.

Key players in global Stem Cell Alopecia Treatment market include:

APEX Biologix, Belgravia Center, RepliCel, Riken Research Institute, Kerastem, Sanford Burnham Prebys Medical Discovery Institute

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=15102&utm_source=ITN&utm_medium=003

Global Stem Cell Alopecia Treatment Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Stem Cell Alopecia Treatment s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Stem Cell Alopecia Treatment Market:

Stem Cell Alopecia Treatment market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Stem Cell Alopecia Treatment Market: Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Stem Cell Alopecia Treatment Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Stem Cell Alopecia Treatment Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Stem Cell Alopecia Treatment Market, By Deployment Model

5.1 Overview

6 Stem Cell Alopecia Treatment Market, By Solution

6.1 Overview

7 Stem Cell Alopecia Treatment Market, By Vertical

7.1 Overview

8 Stem Cell Alopecia Treatment Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Stem Cell Alopecia Treatment Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/?utm_source=ITN&utm_medium=003

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Stem Cell Alopecia Treatment Market Size, Stem Cell Alopecia Treatment Market Analysis, Stem Cell Alopecia Treatment Market Growth, Verified Market Research

Continued here:
Stem Cell Alopecia Treatment Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 - Instant Tech...

Parkinson’s Traced to Malfunctioning Brain Cells at Birth – Newsmax

People who develop Parkinson's disease at a younger age (before age 50) may have malfunctioning brain cells at birth, according to a study that also identified a drug that may help these patients.

At least 500,000 people in the United States are diagnosed with Parkinson's each year. Most are 60 or older at diagnosis, but about 10% are between 21 and 50.

Parkinson's is a neurological disease that occurs when brain neurons that make dopamine become impaired or die. Dopamine helps coordinate muscle movement.

Symptoms get worse over time and include slow gait, rigidity, tremors, and loss of balance. There is currently no cure.

"Young-onset Parkinson's is especially heartbreaking because it strikes people at the prime of life," said study co-author Dr. Michele Tagliati, director of the Movement Disorders Program at Cedars-Sinai Medical Center in Los Angeles.

"This exciting new research provides hope that one day we may be able to detect and take early action to prevent this disease in at-risk individuals," he said in a hospital news release.

For the study, Tagliati and colleagues generated special stem cells from the cells of patients with young-onset Parkinson's disease. These stem cells can produce any cell type of the human body. Researchers used them to produce dopamine neurons from each patient and analyzed those neurons in the lab.

The dopamine neurons showed two key abnormalities: buildup of a protein called alpha-synuclein, which occurs in most forms of Parkinson's disease; and malfunctioning lysosomes, structures that act as "trash cans" for the cell to break down and dispose of proteins. This malfunction could result in a buildup of alpha-synuclein, the researchers said.

"Our technique gave us a window back in time to see how well the dopamine neurons might have functioned from the very start of a patient's life," said senior author Clive Svendsen, director of the Cedars Sinai Board of Governors Regenerative Medicine Institute.

"What we are seeing using this new model are the very first signs of young-onset Parkinson's," Svendsen said in the release. "It appears that dopamine neurons in these individuals may continue to mishandle alpha-synuclein over a period of 20 or 30 years, causing Parkinson's symptoms to emerge."

The study was published Jan. 27 in the journalNature Medicine.

The researchers also tested drugs that might reverse the neuron abnormalities. A drug called PEP005 already approved by the U.S. Food and Drug Administration for treating precancers of the skin reduced elevated levels of alpha-synuclein both in mice and in dopamine neurons in the lab.

The investigators plan to determine how PEP005, which is available in gel form, might be delivered to the brain to potentially treat or prevent young-onset Parkinson's.

They also want to find out whether the abnormalities in neurons of young-onset Parkinson's patients also exist in other forms of Parkinson's.

Excerpt from:
Parkinson's Traced to Malfunctioning Brain Cells at Birth - Newsmax

Will Dialysis Become a Thing of the Past? – Jewish Link of Bronx, Westchester and Connecticut

By Ken Stephens | February 06, 2020

Prof. Benny Dekel (Credit: Roland Metzger)

A groundbreaking study has shown that it is possible to rejuvenate damaged kidneys and improve their function, a procedure that could reverse chronic kidney disease, offsetting the need for dialysis. This is the first breakthrough in decades to combat this disease, often precipitated by hypertension and diabetes, and which affects a whopping 10% of the population worldwide.

The study was conducted by Professor Benjamin Dekel, head of Pediatric Nephrology and the Pediatric Stem Cell Research Institute in the Edmond and Lily Safra Childrens hospital at Sheba Medical Center, and published this week in the prestigious Cell Reports medical journal.

In past studies, researchers discovered that the adult kidney constantly renews itself over time through the activity of colonies of cells that replace lost and degenerated cells in the kidney. Prof. Dekel and his team have now developed an innovative technology that involves the extraction of such healthy kidney cells from diseased kidneys. These cells are then expanded into large numbers within a laboratory environment. By generation of three-dimensional cultures called kidney spheres, the cells show improved function to generate new kidney tissue and replace lost cells. The new cells are then reintroduced into the kidney where they rebuild it, positively influencing neighboring cells and improving its function (see diagram).

One of the most significant aspects of the discovery is that the newly developed technology uses the patients own cells, thereby circumventing the need for immunosuppression as well as problems associated with immune rejection.

Thus far, the method has been tested on mice, where the cells have shown their ability to generate new renal structures, associated with an ability to be retained for a long time once administered into the host kidney. The treated mice displayed improved renal function.

By focusing on improving and stabilizing renal function, this treatment has the potential to help millions of patients with chronic kidney disease and who have yet to require dialysis treatment.

These astounding results will be studied in clinical trials on patients with renal failure by the KidneyCure Bio firm, which commercialized this technology.

Prof. Benjamin Dekel, who led the project said, The breakthrough in this technology, which was developed at the Sheba Medical Center, is not only in the ability to maintain the kidney-renewing cells outside the body, but also in the ability to multiply them and generate large numbers of cells and make them function properly using the 3-D cultures. This is important news for patients with chronic kidney disease, who hopefully will benefit from these discoveries in the coming years. The ability to generate new kidney tissue (to replace the damaged tissue) could help millions of patients worldwide who suffer from kidney disease.

The trailblazing research was carried out by senior researchers Dr. Orit Harari-Steinberg, Dr. Dorit Omer, and Ms. Yehudit Gnatek from the Pediatric Stem Cell Research Institute, under the leadership of Prof. Dekel.

Collaborators include: Dr. Zohar Dotan, Head of Uro-Oncology Service from the urology department at Sheba Medical Center; Dr. Tomer Kalisky and co-workers from Bar Ilan University; and Prof. Yaron Fuchs and co-workers from The Technion.

By Ken Stephens

Read more:
Will Dialysis Become a Thing of the Past? - Jewish Link of Bronx, Westchester and Connecticut

Scientists create ‘Chemical gardens’ that can be used as bone substitute materials – University of Birmingham

Calcium phosphate tubular structures

A new way of making bone-replacement materials that allows for cells to grow around and inside them has been developed by researchers at the University of Birmingham.

The team adopted a novel approach called chemobrionics, in which chemical components are controllably driven to react together in specific ways, enabling the self-assembly of intricate bio-inspired structures.

Scientists first observed these life-like chemical gardens several hundred years ago, but recent renewed interest in the field of chemobrionics has seen researchers using these techniques to design new materials at the micro- and nanoscale.

The Birmingham researchers set out to explore whether chemobrionics could also be harnessed for biotechnological applications.

Lead author Erik Hughes, of the School of Chemical Engineering at the University of Birmingham, explains We set out to investigate if chemobrionics could be used to form architectures that are chemically and structurally similar to human bone. Once a method of generating such structures is established, the natural next step forward is to evaluate if chemobrionic materials can provide ideal frameworks for bone regeneration.

The team used a calcium-loaded gel layered under a phosphate solution, and succeeded in growing long microscale hollow tubes of hydroxyapatite material that is similar in composition to natural bone. Hydroxyapatite is commonly used as a bone substitute material, but it is typically manufactured as a powder or as a hard block, which then needs to be shaped with further processing.

The individual structures grown by the Birmingham team are approximately as thick as a strand of human hair. These tubes possess distinctive features, including porous surfaces that promote interactions with cells. Published in RSC Biomaterials Science, the study demonstrates the similarity of the tubes to many of the structures found in bone tissue, such as osteons long cylindrical channels in bone that house blood vessels.

We can find lots of examples of chemobrionic principles at work in nature, explains Erik. For example, on the ocean floor, we see hot mineral-rich fluids emitted from hydrothermal vents that react with the cool seawater to form chimney-like structures. We are exploiting these same mechanisms to make these new structures for applications in regenerative medicine.

The team have tested the ability of the tubes to support cell attachment, viability and growth in the laboratory using stem cells. They were able to show extensive spreading of the cells upon and extending within the tubes after only 48 hours, indicating favourable cell-material interactions.

Using chemobrionics to produce materials that are biocompatible is a relatively new approach, but we are really excited by its potential, says co-first author Miruna Chipara, who is also based in the School of Chemical Engineering at the University of Birmingham. In particular, the way these structures promote cellular integration means they could be widely useful for bone regeneration.

The next steps for the researchers include carrying out further tests to demonstrate the properties of the tubular materials and how they may be modified to improve tissue regeneration. The researchers are hopeful that their work will lead to the development of a new class of chemobrionic bone substitute materials.

Originally posted here:
Scientists create 'Chemical gardens' that can be used as bone substitute materials - University of Birmingham